Overview Pharmacokinetics Indication Mode of action Adverse reactions Warning and risk References
ChemicalBook > CAS DataBase List > Clindamycin hydrochloride

Clindamycin hydrochloride

Overview Pharmacokinetics Indication Mode of action Adverse reactions Warning and risk References
Product Name
Clindamycin hydrochloride
CAS No.
21462-39-5
Chemical Name
Clindamycin hydrochloride
Synonyms
CLINDAMYCIN HCL;ClindaMycin-d3;CLEOCIN;Dalacin;7(S)-CHLORO-7-DEOXYLINCOMYCIN;Clindamycin hydrochloride, nonsterile;U-21251F;dalacina;Dalacin S;Lujiemycin
CBNumber
CB2398837
Molecular Formula
C18H34Cl2N2O5S
Formula Weight
461.44
MOL File
21462-39-5.mol
More
Less

Clindamycin hydrochloride Property

Melting point:
141°C
storage temp. 
2-8°C
solubility 
H2O: 50 mg/mL, clear, colorless
form 
Solid
color 
White to Off-White
BRN 
4070786
Stability:
Hygroscopic
InChI
InChI=1/C18H33ClN2O5S.ClH/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H/t9-,10+,11-,12+,13-,14+,15+,16+,18+;/s3
InChIKey
AUODDLQVRAJAJM-XJQDNNTCSA-N
SMILES
[C@@H]1([C@@H]([C@H](C)Cl)NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](O)[C@H](O)[C@H]([C@@H](SC)O1)O.Cl |&1:0,1,2,8,10,17,19,21,22,r|
CAS DataBase Reference
21462-39-5(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-36-37/39
WGK Germany 
2
RTECS 
GF2275000
F 
10
HS Code 
29419000
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H317May cause an allergic skin reaction

H319Causes serious eye irritation

H362May cause harm to breast-fed children

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P263Avoid contact during pregnancy/while nursing.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
C5269
Product name
Clindamycin hydrochloride
Purity
lincosamide antibiotic
Packaging
10mg
Price
$99.2
Updated
2024/03/01
Sigma-Aldrich
Product number
C5269
Product name
Clindamycin hydrochloride
Purity
lincosamide antibiotic
Packaging
50mg
Price
$287
Updated
2024/03/01
Sigma-Aldrich
Product number
C5269
Product name
Clindamycin hydrochloride
Purity
lincosamide antibiotic
Packaging
100mg
Price
$482
Updated
2024/03/01
Sigma-Aldrich
Product number
C2250000
Product name
Clindamycin hydrochloride
Purity
European Pharmacopoeia (EP) Reference Standard
Packaging
c2250000
Price
$220
Updated
2024/03/01
Tocris
Product number
4822
Product name
Clindamycin hydrochloride
Purity
≥98%(HPLC)
Packaging
50
Price
$305
Updated
2021/12/16
More
Less

Clindamycin hydrochloride Chemical Properties,Usage,Production

Overview

Clindamycin [7-chloro-lincomycin] is a semisynthetic derivative of lincomycin and was introduced in the 1960s as an antibiotic. It is available as clindamycin hydrochloride for oral administration in capsules, as clindamycin phosphate for intramuscular or intravenous injection, and as clindamycin palmitate for oral suspensions[3-5]. In vitro, its spectrum of activity includes staphylococci, streptococci and pneumococci, most anaerobic bacteria [including over 90% of Bacteroides fragilis], Chlamydia trachomatis and certain protozoa. Like penicillin, it has activity against group A and B streptococci, microaerophilic streptococci and most Streptococcus pneumoniae. It does not, however, have activity against the enterococci [3-5]. Like cloxacillin and the cephalosporins, clindamycin possesses activity against Staphylococcus aureus. It has broader anaerobic coverage than most cephalosporins, but has virtually no activity against aerobic Gram-negative bacteria[3, 4]. With its excellent activity against both Gram-positive cocci and Gram-positive or-negative anaerobes, clindamycin has a role in the treatment of head and neck, respiratory, bone and soft tissue, abdominal, and pelvic infections[1-5].

Figure 1 The chemical structure of the clindamycin hydrochloride

Pharmacokinetics

When given orally, clindamycin is well absorbed and peak concentrations are found after about 45 min. It is metabolized into three major, biologically active derivatives and is mainly excreted into the bile, with about 20% excreted by the kidneys[6]. The normal elimination half-life of about 2 to 4 h is not altered in patients with severe renal disease, but impaired liver function leads to a prolongation of elimination[7].
Clindamycin is purportedly well absorbed(90%) from the gastrointestinal tract, and high concentrations are achieved in most tissues including neutrophils, bone(60%) and joints
[85%] but not in the central nervous system. Recent data indicate that the true absorption of clindamycin may be closer to 50%, and, paradoxically, higher levels are obtained in patients with advanced human immunodeficiency virus(HIV) infection[75% absorption], possibly as a result of decreased hepatic metabolism[8]. Previous studies indicating high absorption may have been measuring an inactive metabolite. The drug is metabolized and excreted by the liver, and dose modifications are recommended for hepatic failure or concomitant renal and hepatic dysfunction. The half-life is 2 to 2.5 h, but may be prolonged to 8 to 12 h in patients with severe liver disease[2]. Biliary excretion of active drug and metabolites results in prolonged activity of clindamycin within the intestine, with effects on gastrointestinal flora for up to two weeks. This may be relevant to both the development and duration of Clostridium difficile-associated colitis. Clindamycin is available as oral tablets(150 and 300 mg), parenteral injection(intramuscular or intravenous), and topical and vaginal formulations. Usual parenteral doses are 600 mg every 6 to 8 h to 900 mg every 8 h. Typical oral doses are 150 to 450 mg qid. Topical formulations include a 2% ointment and 2% vaginal gel.

Indication

Clindamycin hydrochloride is used for the treatment of serious infections caused by susceptible anaerobic bacteria, including Peptostreptococcus, anaerobic streptococci, Clostridium, Bacteroides spp., spp., and microaerophilic streptococci[9]. It may be useful in the treatment of polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. It is also used for treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are faced with drug resistance or are intolerant to many other antibiotics. It may also be used vaginally to treat vaginosis caused by Gardnerella vaginosa[9]. Given clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, it may be particularly useful for treating necrotizing fasciitis. It is also administrated topically to treat acne[9,10].
Furthermore, it is active against organisms such as Plasmodium, Toxoplasma, Babesia, and Pneumocystis spp. Clindamycin is the drug of choice for prophylaxis of Toxoplasma chorioretinitis in newborn infants[11] and is part of recommended regimens against both Babesia microti and Babesia divergens[12]. In combination with pyrimethamine or primaquine, it is an alternative regimen for the treatment of toxoplasmosis and pneumocystosis, respectively[11, 13]. Clinical trials from the 1970s and 1980s have shown the efficacy, safety, and practicability of the treatment of Plasmodium falciparum malaria with clindamycin[14-16].

Mode of action

Clindamycin acts by inhibiting bacterial protein synthesis through binding to the 23S rRNA of 50S ribosome[9, 10]. As a result, it exerts a prolonged post-antibiotic effect. It may decrease toxin production and increase microbial opsonization and phagocytosis even at sub-inhibitory concentrations. Although chemically dissimilar to erythromycin and the macrolide antibiotics, in vitro antagonism occurs as a result of a similar site of binding and mechanism of action. In addition, topical clindamycin can reduce the free fatty acid concentrations on the skin and further suppresses the growth of Propionibacterium acnes[Corynebacterium acnes], an anaerobe found in sebaceous glands and follicles[9, 10].

Adverse reactions

Adverse effects associated with the clindamycin hydrochloride may include nausea[may be dose-limiting], diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs at a ratio of 0.01 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis[including pseudomembranous colitis] have been reported with the use of topical and systemic clindamycin[9]. The application of clindamycin can also cause resistant-clostridium difficile colitis. Hypersensitivity reactions include mild to moderate morbilliform-like[maculopapular] skin rashes are the most frequently reported adverse reactions[10]. Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Some skin reactions such as Toxic Epidermal Necrolysis, some with fatal outcome, have been reported[10]. Cases of Acute Generalized Exanthematous Pustulosis[AGEP], erythema multiforme, some resembling Stevens-Johnson syndrome, anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported. For skin and mucous membrane, reactions such as pruritus, angioedema, vaginitis and few cases of exfoliative dermatitis have also been observed. Some liver and renal abnormalities including jaundices, azotemia, oliguria have also been observed[10].

Warning and risk

Special tips should be concerned when administrating clindamycin[17].
People who are allergic to clindamycin or lincomycin should be disabled for using it.
The patients should tell his/her doctor if he/she has the following several cases: colitis, Crohn's disease, or other intestinal disorder; eczema, or allergic skin reaction; liver disease; asthma or a severe allergic reaction to aspirin; an allergy to yellow food dye.
Though it still lacks of information regarding whether clindamycin will harm an unborn baby, you’d better tell your doctor if you are pregnant or plan to become pregnant during treatment. It may not be safe to breast-feed a baby while you are using clindamycin. Ask your doctor about any risks.
Clindamycin injection may contain an ingredient that can cause serious side effects or death in very young or premature babies. Do not give this medicine to a child without medical advice. Call your doctor for help if you get some adverse reactions.

References

  1. Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. Douglas and Bennett’s Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995:334-6.
  2. O’Hanley PD, Tam JY, Holodniy M. Infectious disorders. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Melmon and Morrelli’s Clinical Pharmacology: Basic Principles in Therapeutics, 3rd edn. New York: McGraw-Hill, 1992:710.
  3. Falagas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am 1995;79:845-67.
  4. Klainer AS. Clindamycin. Med Clin North Am 1987;71:1169-75.
  5. Dhawan, V. K., & Thadepalli, H.[1982]. Clindamycin: a review of fifteen years of experience. Reviews of Infectious Diseases, 4[6], 1133-1153.
  6. Wagner, J. G., E. Novak, N. C. Patel, C. G. Chidester, and W. Lummis. 1968. Absorption, excretion and half-life of clindamycin in normal adult males. Am. J. Med. Sci. 256:25–37.
  7. Dhawan, V. K., and H. Thadepalli. 1982. Clindamycin: a review of fifteen years of experience. Rev. Infect. Dis. 4:1133–1153.
  8. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agent Chemother 1993; 37:1137-43.
  9. https://www.drugbank.ca/drugs/DB01190
  10. https://www.rxlist.com/clindamycin-drug.htm
  11. St. Georgiev, V. 1994. Management of toxoplasmosis. Drugs 48:179–188.
  12. Homer, M. J., I. Aguilar-Delfin, S. R. Telford, P. K. Krause, and D. H. Persing. 2000. Babesiosis. Clin. Microbiol. Rev. 13:451–469.
  13. Fishman, J. A. 1998. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42:1309–1314.
  14. El Wakeel, E. S., Homeida, M. M., Ali, H. M., Geary, T. G., & Jensen, J. B.[1985]. Clindamycin for the treatment of falciparum malaria in sudan. American Journal of Tropical Medicine & Hygiene, 34[6], 1065.
  15. Kremsner, P. G., Zotter, G. M., Feldmeier, H., Graninger, W., Westerman, R. L., & Rocha, R. M.[1989]. Clindamycin treatment of falciparum malaria in brazil. Journal of Antimicrobial Chemotherapy, 23[2], 275-81.
  16. Clyde, D. F., Gilman, R. H., & Mccarthy, V. C.[1975]. Antimalarial effects of clindamycin in man. American Journal of Tropical Medicine & Hygiene, 24[2], 369-70.
  17. https://www.drugs.com/clindamycin.html

Chemical Properties

White Solid

Originator

Dalacin-C,Diethelm,Switz.,1968

Uses

antibacterial, inhibits protein synthesis

Uses

Clindamycin hydrochloride is a salt of clindamycin, a semi-synthetic lincosamide. The hydrochloride salt forms at the basic N-ethylproline moiety and is the preferred pharmaceutical formulation. Like other members of the lincosamide family, clindamycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Clindamycin hydrochloride acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Clindamycin hydrochloride has been extensively studied with over 8,000 literature citations.

Uses

Labelled Clindamycin. Semi-synthetic antibiotic prepared from Lincomycin;Labeled Clindamycin, intended for use as an internal standard for the quantification of Clindamycin by GC- or LC-mass spectrometry.

Definition

ChEBI: Clindamycin hydrochloride is a S-glycosyl compound.

Manufacturing Process

The following procedure is described in US Patent 3,475,407. A solution of 50 g of lincomycin hydrochloride, 120 g of triphenylphosphine, and 500 ml of acetonitrile in a 3 liter flask equipped with a stirrer was cooled in an ice bath and 500 ml of carbon tetrachloride was added in one portion. The reaction mixture was then stirred for 18 hours without addition of ice to the cooling
bath. The reaction was evaporated to dryness under vacuum on a 50° to 60°C water bath, yielding a clear, pale yellow viscous oil. An equal volume of water was added and the mixture shaken until all of the oil was dissolved. The resulting suspension of white solid (Ph3PO) was filtered through a sintered glass mat and discarded. The filtrate was adjusted to pH 11 by addition of 6 N aqueous sodium hydroxide. A solid precipitated.
The resulting slurry was extracted with four 300 ml portions of chloroform. The aqueous phase was discarded. The combined chloroform extract was washed once with 100 ml of saturated aqueous sodium chloride solution and the sodium chloride phase was discarded. The chloroform phase was evaporated to dryness under vacuum on a 50° to 60°C water bath and an equal volume of methanol was added to the residue and the resulting solution heated at reflux for 1 hour. The methanol solution was evaporated to dryness under vacuum on a 50° to 60°C water bath. The residue was a clear pale yellow viscous oil. An equal volume of water and 10 ml of 37% aqueous HCl was added and the resultant was shaken until the oil dissolved and a white solid (more Ph3PO) remained in suspension. The suspension was filtered through a sintered glass mat at pH 1 to 2 and the solid discarded.
The filtrate was extracted twice with 100 ml of carbon tetrachloride. The carbon tetrachloride phase was discarded. The aqueous phase was adjusted to pH 11 by addition of 6 N aqueous sodium hydroxide and extracted four times with 300 ml portions of chloroform. The combined chloroform extract was washed three times with 100 ml of saturated aqueous sodium chloride solution and the sodium chloride phase was discarded. The chloroform extract was dried over anhydrous magnesium sulfate, filtered and the filtrate evaporated to dryness under vacuum on a 50° to 60 °C water bath. The residue was a clear, colorless glass weighing 45 g analyzing about 95% 7(S)- chloro-7-deoxylincomycin. To the crude product there was added 100 ml of ethanol with warming until a clear solution was obtained. Then 150 ml ethyl acetate was added and the resultant filtered through a glass mat and the filtrate adjusted to pH 1 by the addition of saturated ethanolic HCl. Crystallization soon occurred. The resultant was allowed to stand at 0°C for 18 hours and then filtered through a sintered glass mat. The solid was dried under vacuum at 60°C for 18 hours yielding 35 g, a 67% yield of 7(S)-chloro- 7-deoxylincomycin hydrochloride as an ethanol solvate.

brand name

Cleocin (Pharmacia & Upjohn).

Therapeutic Function

Antibacterial

General Description

Chemical structure: macrolide

Biochem/physiol Actions

Clindamycin hydrochloride is highly effective against anaerobic species.

Contact allergens

This lincosanide antibiotic is used in topical form for acne, or systemically has been responsible for exanthematous rashes and acute generalized exanthematous pustulosis.

Clinical Use

Clindamycin is recommended for the treatment of a widevariety of upper respiratory, skin, and tissue infections causedby susceptible bacteria. Its activity against streptococci,staphylococci, and pneumococci is indisputably high, and it isone of the most potent agents available against somenon–spore-forming anaerobic bacteria, the Bacteroides spp.in particular. An increasing number of reports of clindamycin-associated GI toxicity, which range in severity fromdiarrhea to an occasionally serious pseudomembranous colitis,have, however, caused some clinical experts to call for areappraisal of the role of this antibiotic in therapy.Clindamycin- (or lincomycin)-associated colitis may be particularlydangerous in elderly or debilitated patients and hascaused deaths in such individuals. The colitis, which is usuallyreversible when the drug is discontinued, is now believedto result from an overgrowth of a clindamycin-resistant strainof the anaerobic intestinal bacterium Clostridium difficile.229The intestinal lining is damaged by a glycoprotein endotoxinreleased by lysis of this organism.
The glycopeptide antibiotic vancomycin has been effectivein the treatment of clindamycin-induced pseudomembranouscolitis and in the control of the experimentally induced bacterial condition in animals. Clindamycin shouldbe reserved for staphylococcal tissue infections, such as cellulitisand osteomyelitis, in penicillin-allergic patients andfor severe anaerobic infections outside the central nervoussystem. Ordinarily, it should not be used to treat upper respiratorytract infections caused by bacteria sensitive to othersafer antibiotics or in prophylaxis.

Veterinary Drugs and Treatments

Clindamycin products are approved for use in dogs and cats. The labeled indications for dogs include wounds, abscesses and osteomyelitis caused by Staphylococcus aureus. Because clindamycin has excellent activity against most pathogenic anaerobic organisms, it is also used extensively for those infections. Clindamycin is used for a variety of protozoal infections, including toxoplasmosis. For further information, refer to the Dosage or Pharmacology sections.

storage

-20°C

Clindamycin hydrochloride Preparation Products And Raw materials

Raw materials

Ethanol Lincomycin Lincomycin hydrochloride monohydrate

Preparation Products

More
Less

Clindamycin hydrochloride Suppliers

Australia 1 Austria 1 Belgium 2 Brazil 3 Canada 4 China 477 Czech Republic 2 Europe 3 France 2 Germany 12 Greece 1 India 57 Italy 4 Japan 1 Jordan 1 Malaysia 1 Mexico 2 Philippines 1 Poland 3 South Korea 1 Spain 4 Switzerland 6 The Netherlands 2 United Kingdom 15 United States 73 Global 679
Wuhan Feiyue Biotechnology Co., LTD
Tel
027-87002654 18062720658
Email
andydeng@feiyuebio.com
Country
China
ProdList
805
Advantage
58
Hubei Henghua Technology Co., Ltd.
Tel
18064208139
Email
2912268575@qq.com
Country
China
ProdList
1363
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15839
Advantage
69
future industrial shanghai co., ltd
Tel
400-0066400 13621662912
Fax
021-55660885
Email
sales@jonln.com
Country
China
ProdList
1995
Advantage
65
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44688
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35896
Advantage
56
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
chenyj@titansci.com
Country
China
ProdList
14103
Advantage
59
Accela ChemBio Co.,Ltd.
Tel
021-50795510 4000665055
Fax
021-50795055
Email
sales@accelachem.com
Country
China
ProdList
11655
Advantage
64
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8836
Advantage
52
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com
Country
China
ProdList
4554
Advantage
62
Maya High Purity Chemicals
Tel
+86 (573) 82222445 (0)18006601000 452520369
Fax
+86 (573) 82222643
Email
sales@maya-r.com
Country
China
ProdList
11707
Advantage
57
ZhengZhou HuaWen Chemical Co.Ltd
Tel
0370-2785118 17550508557
Fax
QQ：3470079902
Email
675141927@qq.com
Country
China
ProdList
3203
Advantage
55
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9658
Advantage
60
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2865
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4727
Advantage
58
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Fax
021-55068248
Email
shyysw007@163.com
Country
China
ProdList
4940
Advantage
60
T&W GROUP
Tel
021-61551611 13296011611
Fax
＋86 21-50676805
Email
contact@trustwe.com
Country
China
ProdList
9895
Advantage
58
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Fax
+86 755 28094224
Country
China
ProdList
4496
Advantage
50
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9865
Advantage
52
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9891
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
Simagchem Corp.
Tel
86 592 2680277
Fax
0086 592 2680237
Email
sale@simagchem.com
Country
China
ProdList
430
Advantage
55
The future of Shanghai Industrial Co., Ltd.
Tel
021-61552785
Fax
021-55660885
Email
sales@shshiji.com
Country
China
ProdList
9545
Advantage
55
Shanghai Ruji Biology Technology Co., Ltd.
Tel
+86-21-65211385-8001 36031160
Fax
+86-21-65211385-8004
Email
sales@shruji.com
Country
China
ProdList
3224
Advantage
55
VOT INTERNATIONAL BUSINESS CO.,LTD
Tel
0536-2456718
Fax
0536-8231856
Country
China
ProdList
226
Advantage
55
Cantotech Chemicals, Ltd.
Tel
86-0755-86635001
Fax
86-0755-22642228
Email
cantotech@126.com
Country
China
ProdList
4566
Advantage
55
Nanjing Dulai Biotechnology Co., Ltd.
Tel
025-84699383-8003 18013301590
Fax
025-84699383-8003
Email
njduly@126.com
Country
China
ProdList
971
Advantage
55
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4674
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
Shanghai TaoSu Biochemical Technology Co., Ltd.
Tel
021-33632979
Fax
021-34692979
Email
info@tsbiochem.com
Country
China
ProdList
8065
Advantage
58
Shenzhen Shijingu Technology Co., Ltd
Tel
(0086)755-61930359 (0086)18038192047
Fax
(0086)755-84556470
Email
jo@pharmade.com
Country
China
ProdList
279
Advantage
58
Shanghai BeiZhuo Biotech Co., Ltd.
Tel
021-61119791,13386096464
Fax
021-50190009
Email
bzswkf@foxmail.com
Country
China
ProdList
3921
Advantage
50
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
1734
Advantage
58
Shanghai JONLN Reagent Co., Ltd.
Tel
400-0066400 13621662912
Fax
021-55660885
Email
422131432@qq.com
Country
China
ProdList
9978
Advantage
55
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Fax
+86-21-61629029
Email
product02@bidepharm.com
Country
China
ProdList
41462
Advantage
60
Shanghai DiBai Chemicals Co., Ltd.
Tel
021-54359730 400-008-9730
Fax
021-54353864
Email
info@chemxyz.com
Country
China
ProdList
3991
Advantage
60
Finetech Industry Limited
Tel
027-87465837 19945049750
Fax
027-8777-2287
Email
sales@finetechnology-ind.com
Country
China
ProdList
9648
Advantage
58
Shanghai CanSpecsci Instrument Co., Ltd.
Tel
400-6087598 15021221957
Fax
4006087598-8012
Email
order@canspecsci.com
Country
China
ProdList
2045
Advantage
56
Suzhou yacoo science co.,Ltd
Tel
0512-87182056 18013166090
Fax
0512-87182056
Email
lingling.qi@yacoo.com.cn
Country
China
ProdList
7295
Advantage
60
Wuhan Dahua Pharmaceutical Co., Ltd.
Tel
027-59262863 13277907145 3091977954
Fax
027-59420980
Country
China
ProdList
4943
Advantage
58
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939 15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
16166
Advantage
55
Wuhan Dahua Weiye Pharmaceutical Chemical Co., Ltd.
Tel
027-59420981,18702770802
Fax
027-83322098
Country
China
ProdList
1975
Advantage
50
Shanghai Song Yuan Chemical Technology Co., Ltd.
Tel
010-1234567 18521000990
Fax
86-021-33275113
Email
sonyuanchemical@163.com
Country
China
ProdList
6479
Advantage
50
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Fax
025-68650336
Email
info@adooq.cn
Country
China
ProdList
2990
Advantage
60
Hubei Jusheng Technology Co.,Ltd
Tel
027-59599241 18871490274
Fax
027-59599241
Email
1400878000@qq.com
Country
China
ProdList
9958
Advantage
58
More
Less

View Lastest Price from Clindamycin hydrochloride manufacturers

Henan Suikang Pharmaceutical Co.,Ltd.
Product
Clindamycin hydrochloride 21462-39-5
Price
US $0.00/kg
Min. Order
25kg
Purity
＞800ug/mg
Supply Ability
10tons
Release date
2024-05-08
Hebei Zhuanglai Chemical Trading Co Ltd
Product
Clindamycin HCl 21462-39-5
Price
US $150.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
500kg
Release date
2024-11-19
Hebei Zhuanglai Chemical Trading Co Ltd
Product
Clindamycin HCl 21462-39-5
Price
US $150.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
500kg
Release date
2024-11-22

21462-39-5, Clindamycin hydrochlorideRelated Search:

Chlortetracycline hydrochloride Lincomycin hydrochloride PIERICIDIN A Rituximab CLINDAMYCIN PALMITATE HYDROCHLORIDE Hydrocortisone sodium succinate PotassiuM sodiuM Dehydroandrographolide Succinate Lincomycin CLINDAMYCIN-HYDROCHLORIDE-ETHANOL(INTERMEDIATE) Topotecan hydrochloride Clindamycin phosphate Clindamycin B 7-epi-Clindamycin ClindaMycin B PalMitate Lercanidipine hydrochloride Raloxifene hydrochloride Clindamycin Hydrochloride Monohydrate,CLINDAMYCIN HYDROCHLORIDE ETHANOLATE Clindamycin hydrochlorid capsules Clindamycin Hcl

  • Clindaymcin Hydrochloride BP98,USP25,EP97
  • L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(2S,4R)-1-methyl-4-propyl-2-pyrrolidinylcarbonylamino-1-thio-, monohydrochloride
  • CLINDAMYCINHYDROCHLORIDE,CRYSTAL
  • CLINDAMYCINHYDROCHLORIDE,USP
  • Clindamycin hydrochloride, Antibiotic for Culture Media Use Only
  • CLINDAMYCIN HC
  • Lujiemycin
  • monohydrochloride,(2s-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio
  • CLINDAMYCIN HCI
  • (7S)-7CHLORO-7-DEOXYLINCOMYCIN HCL
  • Clindamycin IMP
  • CLINDAMYCIN HYDROCHLORIDE, LINCOSAMI
  • Clindamycin hydrochloride, nonsterileUSP, ≥ 860 μg/mg
  • (2S-trans)-Methyl 7-Chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2- pyrrolidinyl]carbonyl]amino]-1-thio-L-threo-α-D-galactooctopyranoside Hydrochloride
  • Clindamycin hydrochloride Solution, 1000ppm
  • Clindamycin Impurity 14(Clindamycin Phosphate EP Impurity E)
  • (4R)-N-[(1S,2S)-2-chloro-1-[(3R,4R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide hydrochloride
  • Methyl-7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-L-threo-α-D-galacto-octopyranoside hydrochloride
  • (2S-TRANS)-METHYL 7-CHLORO-6,7,8-TRIDEOXY-6[[(1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL]AMINO]-1-THIO-L-THREO-ALPHA-D-GALACTO-OCTOPYRANOSIDE
  • (7S)-7-CHLORO-7-DEOXYLINCOMYCIN HYDROCHLORIDE
  • 7(S)-CHLORO-7-DEOXYLINCOMYCIN
  • 7(S)-CHLORO-7-DEOXYLINCOMYCIN HCL
  • 7[S]-CHLORO-7-DEOXYLINCOMYCIN HYDROCHLORIDE
  • CLEOCIN
  • CLEOCIN HYDROCHLORIDE
  • CLINDAMYCIN HCL
  • CLINDAMYCIN HYDROCHLORIDE
  • U-21251F
  • (2S-trans)-Methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-L-threo-alpha-D-galacto-octothiopyranoside monohydrochloride
  • (7S)-7-Chloro-7-deoxylincomycin hydrochloride, Cleocin
  • 7-chloro-7-deoxylincomycinhydrochloride
  • clindimycinhydrochloride
  • clindomycinhydrochloride
  • dalacina
  • Clindamycin hydrochloride, nonsterile
  • Clidamacin
  • Dalacin
  • Dalacin S
  • Panancocin
  • (2S-trans)-Methyl 7-Chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-Methyl-4-propyl-2- pyrrolidinyl]carbonyl]aMino]-1-thio-
  • ClindaMycin hydrochloride Antipyrotic
  • ClindaMycin HCL USP30 EP5 BP2007
  • ClindaMycin-d3
  • Clindamycin Base & Phosphate
  • Clindamycin hydrochloride,(7S)-7-Chloro-7-deoxylincomycin hydrochloride, Cleocin
  • 7-Chloro-7-deoxylincoMycin hydrochloride, 7-ChlorolincoMycin hydrochloride
  • (L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-, hydrochloride (1:1))
  • Clindamycin hydrochloride CRS
  • Clinimycin HCl
  • Sobelin HCl
  • indamycin HydrochL
  • Clindamycin hydrochloride solution in Methanol, 1000ug/ml
  • Clindamycin hydrochloride (USP, EP, oral grade)
  • (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide hydrochloride
  • Clindamycin hydrochloride salt
  • lindamycin hydrochloride
  • Clindamycin HydrochlorideQ: What is Clindamycin Hydrochloride Q: What is the CAS Number of Clindamycin Hydrochloride Q: What is the storage condition of Clindamycin Hydrochloride Q: What are the applications of Clindamycin Hydrochloride
  • Clindamycin 13C D3 HydrochlorideQ: What is Clindamycin 13C D3 Hydrochloride Q: What is the CAS Number of Clindamycin 13C D3 Hydrochloride Q: What is the storage condition of Clindamycin 13C D3 Hydrochloride Q: What are the applications of Clindamycin 13C D3 Hydrochloride